The following article was published in the Journal of Clinical Hypertension in April 2012: Single‐1Pill Combination of Telmisartan/Amlodipine in Patients with Severe Hypertension: Results from the TEAMSTA Severe HTN Study by Joel M. Neutel, MD; Giusepe Mancia, MD; Henry R. Black, MD; Bjorn Dahlof, MD; Holly Defeo, RN; Ludwin Ley, MD; Richard Vinisko, MS; and on behalf of the TEAMSTA Severe HTN Study Investigators*— DOI: 10.1111/j.1751‐7176.2012.00595.x. Subsequently, the authors identified errors to 2, 3. The correct figures are below and should replace the previously published figures; there are no changes to the figure legends. On page 4, in the following sentence, the authors wish to amend an incorrect numeral; the accurate numeral appears in bold: “Overall, patients with baseline SBP levels of 180 mm Hg to <190 mm Hg and 190 mm Hg to <200 mm Hg achieved substantial mean reductions in SBP of 47.5 mm Hg and 48.8 mm Hg, respectively, with the SPC (Figure 3).”
Figure 2.
Mean reductions (standard error of mean [SEM]) from baseline in seated trough cuff systolic blood pressure (SBP) (panel A) and diastolic blood pressure (DBP) (panel B) by treatment week (note that some SEMs may not be visible as they are too small to reach beyond the border of the symbol), mean seated trough cuff SBP (panel C) and DBP (panel D) by treatment week, and patients assigned to the telmisartan/amlodipine (T/A) or amlodipine (A) groups received telmisartan 80 mg (T80)/amlodipine 5 mg (A5) or A5 for the first 2 weeks, then T80/amlodipine 10 mg (A10) or A10 for the remaining 6 weeks; patients in the T80 group remained on the same treatment for the entire 8 weeks.
Figure 3.
Mean reductions in mean seated trough cuff systolic blood pressure (SBP) from baseline to end of study (week 8) per baseline SBP category; 10‐mm Hg increments. Patients assigned to the telmisartan/amlodipine (T/A) or amlodipine (A) groups received telmisartan 80 mg (T80)/amlodipine 5 mg (A5) or A5 for the first 2 weeks, then T80/amlodipine 10 mg (A10) or A10 for the remaining 6 weeks; patients in the T80 group remained on the same treatment for the entire 8 weeks. DBP indicates diastolic blood pressure.